Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2016 -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines in the fields of hemostasis and anti-complement to address serious medical conditions, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference, being held in New York City February 8-9, 2016.
BIO CEO & Investor Conference – Catalyst Biosciences Presentation Details
Date: Tuesday, February 9, 2016
Time: 8:00 a.m. Eastern Time
Location: Waldorf Astoria, Conrad Room
About Catalyst Biosciences, Inc.
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration (Dry AMD), a condition that can cause visual impairment or blindness for which there are no approved treatments. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
All statements, other than statement of historical facts, included in this press release regarding our strategy, future operations, and plans, including statements relating to the development of the Company’s products, are forward-looking statements. Actual results or events could differ materially from expectations in the forward-looking statements due to various important factors, such as the risk that that trials and studies may be delayed and may not have satisfactory outcomes, potential adverse effects arising from the testing or use of Catalyst's products, and other risks described in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2015. Catalyst does not assume any obligation to update any forward-looking statements, except as required by law.
Investors: Andrew McDonald Managing Director LifeSci Advisors, LLC 646.597.6987 [email protected] Fletcher Payne, CFO Catalyst Biosciences, Inc. 650.871.0761 [email protected] Media: Denise Powell Red House Consulting, LLC 510.703.9491 [email protected]
